Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 422
- Registration Number
- NCT03671018
- Locations
- 🇺🇸
University of Pittsburgh - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 131
- Registration Number
- NCT03669640
- Locations
- 🇺🇸
California Neuropsychopharmacology Clinical Research Institute, LLC, San Diego, California, United States
🇺🇸Synergy San Diego, Lemon Grove, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
- Conditions
- Huntington's Disease
- Interventions
- Other: No Study Drug was Administered in this Study
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 95
- Registration Number
- NCT03664804
- Locations
- 🇺🇸
CenExel Rocky Mountain Clinical Research, LLC, Englewood, Colorado, United States
🇺🇸Georgetown University; Research Division, Psychiatry, Washington, District of Columbia, United States
🇺🇸Hereditary Neurological Disease Centre (HNDC), Wichita, Kansas, United States
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT03653364
- Locations
- 🇵🇱
IN VIVO Sp. z o.o., Bydgoszcz, Poland
🇺🇸Usf Health, Tampa, Florida, United States
🇺🇸Oak Cliff Research Company, LLC, Dallas, Texas, United States
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT03635489
- Locations
- 🇨🇳
the First Hospital of Jilin University, Changchun, China
🇨🇳Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing City, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, China
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 173
- Registration Number
- NCT03629184
- Locations
- 🇺🇸
The Probe Medical Research, Los Angeles, California, United States
🇺🇸Kentucky Pediatric Research Center, Bardstown, Kentucky, United States
🇺🇸Orange County Research Institute, Ontario, California, United States
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT03625141
- Locations
- 🇧🇷
Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil
🇧🇷Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, RS, Brazil
🇧🇷Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 940
- Registration Number
- NCT03622580
- Locations
- 🇺🇸
Orange County Retina Med Group, Santa Ana, California, United States
🇺🇸Kaiser Permanente Riverside Medical Center, Riverside, California, United States
🇺🇸Cumberland Valley Retina PC, Hagerstown, Maryland, United States
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 951
- Registration Number
- NCT03622593
- Locations
- 🇨🇦
Toronto Retina Institute, Toronto, Ontario, Canada
🇨🇦Unity Health Toronto, Toronto, Ontario, Canada
🇺🇸Retina Consultants of Nevada, Las Vegas, Nevada, United States
A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
- Conditions
- Autism Spectrum Disorder
- Interventions
- Other: No Intervention
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 144
- Registration Number
- NCT03611075
- Locations
- 🇺🇸
PCSD Feighner Research, San Diego, California, United States
🇺🇸Southwest Autism Research and Resource Center, Phoenix, Arizona, United States
🇺🇸Harmonex Neuroscience Research, Dothan, Alabama, United States